Previous 10 | Next 10 |
2024-05-28 21:15:02 ET Barclays analyst issues OVERWEIGHT recommendation for INSM on May 28, 2024 07:54PM ET. The previous analyst recommendation was Overweight. INSM was trading at $48.06 at issue of the analyst recommendation. The overall analyst consensus : BUY. C...
Insmed Announces Proposed $500 Million Public Offering of Common Stock PR Newswire BRIDGEWATER, N.J. , May 28, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious...
2024-05-28 17:04:47 ET Gainers: Blue World Acquisition ( BWAQ ) +57% . Insmed ( INSM ) +33% . Vivid Seats ( SEAT ) +8% . Ocular Therapeutix ( OCUL ) +7% . Mind Medicine ( MNMD ) +7% . Losers: Inhib...
2024-05-28 17:00:04 ET Jeffrey Hung from Morgan Stanley issued a price target of $60.00 for INSM on 2024-05-28 14:37:00. The adjusted price target was set to $60.00. At the time of the announcement, INSM was trading at $48.06. The overall price target consensus is at $49...
A look at the top 10 most actives in the United States Pineapple Energy Inc. (PEGY) rose 46.0% to $0.2601 on volume of 655,453,952 shares Sharps Technology Inc. (STSS) rose 141.4% to $0.5174 on volume of 299,690,189 shares Greenwave Technology Solutions Inc. (GWAV) fell 7.4% to $0.0786 on...
2024-05-28 16:00:07 ET Andrea Tan from Goldman Sachs issued a price target of $74.00 for INSM on 2024-05-28 13:27:00. The adjusted price target was set to $74.00. At the time of the announcement, INSM was trading at $46.39. The overall price target consensus is at $46.67...
2024-05-28 14:04:21 ET More on Mid-day movers & stock Semler Scientific: Great Product Can Still Thrive Post Medicare Advantage Semler Scientific, Inc. (SMLR) Q1 2024 Earnings Call Transcript G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript A...
2024-05-28 12:10:00 ET Summary Brensocatib, Insmed's DPP1 inhibitor, showed significant efficacy in the Phase 3 ASPEN study for treating NCFB. Insmed's financial position includes high R&D costs with a solid short-term liquidity ratio but substantial long-term debt. Peak r...
Insmed Incorporated (NASDAQ: INSM) is one of today's top gainers. The company's shares have moved 111.43% on the day to $46.49. Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for t...
2024-05-28 10:00:33 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-09 08:00:06 ET Vamil Divan from Guggenheim issued a price target of $95.00 for INSM on 2024-07-09 06:44:00. The adjusted price target was set to $95.00. At the time of the announcement, INSM was trading at $70.05. The overall price target consensus is at $72.91 w...
Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference PR Newswire —New Graph Depicting 52-Week FEV1 Data Illustrate Significantly Less Decline in Lung Function for Bren...